Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
5(83.3%)
Phase 2
1(16.7%)
6Total
N/A(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07304622Not ApplicableCompleted

Impact of Various Therapeutic Methods on Gait Quality, Physical and Mental Fitness of Postmenopausal Women.

Role: lead

NCT07235228Not ApplicableRecruiting

Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients

Role: lead

NCT07235215Not ApplicableRecruiting

Vivatlac in Irritable Bowel Syndrome II (ViIBS2)

Role: lead

NCT05731232Not ApplicableCompleted

Effects of Vivatlac Synbiotikum in Patients With Irritable Bowel Syndrome

Role: lead

NCT04487834Phase 2Completed

Effects of Vivatlac Baby on Crying Behavior of Colicky Babies

Role: lead

NCT04666324Not ApplicableUnknown

Effects of Multilac Baby on Fecal Calprotectin Levels of Colicky Babies

Role: lead

All 6 trials loaded